Copy link
Copied
One of the world’s biggest drug companies says Australia risks being abandoned as a market for new medicines because it has one of the world’s most prohibitive pricing and approvals systems that may cause millions of patients to lose out on affordable live-saving therapies.
Owen Smith, the CEO of Bristol Myers Squibb’s Australian operations, said on Monday the Albanese government needed to urgently reform a pricing system which provided little commercial incentive for drugmakers to get new medicines listed on the Pharmaceutical Benefits Scheme.
Copy link
